causal

Medications that target incretin hormones lower the risk of illness and death in people with diabetes by improving how the body processes glucose and functions of the heart and blood vessels.

Evidence from Studies

Supporting (2)

Community contributions welcome

Untitled Study

Contradicting (1)

Community contributions welcome

Adverse effects of incretin‐based therapies on major cardiovascular and arrhythmia events: meta‐analysis of randomized trials

Systematic Review With Meta-Analysis

Human

2016 Nov

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Similar Assertions

Medications called incretin-based therapies, used for type 2 diabetes, are associated with better heart health due to their effects on reducing inflammation, lowering blood pressure, and helping with weight loss.

87%

Adults with overweight or obesity who take incretin-based therapies have a lower risk of dying from any cause compared to those who do not, based on combined data from multiple studies.

77%

Medications that target incretin hormones do not raise the likelihood of low blood sugar or pancreatitis in adults who are overweight or obese.

74%